Oligonucleotide-based antiviral strategies.
Identifieur interne : 003F71 ( Main/Merge ); précédent : 003F70; suivant : 003F72Oligonucleotide-based antiviral strategies.
Auteurs : S. Schubert [Allemagne] ; J. KurreckSource :
- Handbook of experimental pharmacology [ 0171-2004 ] ; 2006.
Descripteurs français
- KwdFr :
- ARN catalytique (pharmacologie), ARN catalytique (usage thérapeutique), Animaux, Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Humains, Maladies virales (traitement médicamenteux), Maladies virales (virologie), Oligonucléotides (pharmacologie), Oligonucléotides (usage thérapeutique), Oligonucléotides antisens (pharmacologie), Oligonucléotides antisens (usage thérapeutique), Petit ARN interférent (pharmacologie), Petit ARN interférent (usage thérapeutique).
- MESH :
- pharmacologie : ARN catalytique, Antiviraux, Oligonucléotides, Oligonucléotides antisens, Petit ARN interférent.
- traitement médicamenteux : Maladies virales.
- usage thérapeutique : ARN catalytique, Antiviraux, Oligonucléotides, Oligonucléotides antisens, Petit ARN interférent.
- virologie : Maladies virales.
- Animaux, Humains.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Humans, Oligonucleotides (pharmacology), Oligonucleotides (therapeutic use), Oligonucleotides, Antisense (pharmacology), Oligonucleotides, Antisense (therapeutic use), RNA, Catalytic (pharmacology), RNA, Catalytic (therapeutic use), RNA, Small Interfering (pharmacology), RNA, Small Interfering (therapeutic use), Virus Diseases (drug therapy), Virus Diseases (virology).
- MESH :
- chemical , pharmacology : Antiviral Agents, Oligonucleotides, Oligonucleotides, Antisense, RNA, Catalytic, RNA, Small Interfering.
- chemical , therapeutic use : Antiviral Agents, Oligonucleotides, Oligonucleotides, Antisense, RNA, Catalytic, RNA, Small Interfering.
- drug therapy : Virus Diseases.
- virology : Virus Diseases.
- Animals, Humans.
Abstract
In the age of extensive global traffic systems, the close neighborhood of man and livestock in some regions of the world, as well as inadequate prevention measures and medical care in poorer countries, greatly facilitates the emergence and dissemination of new virus strains. The appearance of avian influenza viruses that can infect humans, the spread of the severe acute respiratory syndrome (SARS) virus, and the unprecedented raging of human immunodeficiency virus (HIV) illustrate the threat of a global virus pandemic. In addition, viruses like hepatitis B and C claim more than one million lives every year for want of efficient therapy. Thus, new approaches to prevent virus propagation are urgently needed. Antisense strategies are considered a very attractive means of inhibiting viral replication, as oligonucleotides can be designed to interact with any viral RNA, provided its sequence is known. The ensuing targeted destruction of viral RNA should interfere with viral replication without entailing negative effects on ongoing cellular processes. In this review, we will give some examples of the employment of antisense oligonucleotides, ribozymes, and RNA interference strategies for antiviral purposes. Currently, in spite of encouraging results in preclinical studies, only a few antisense oligonucleotides and ribozymes have turned out to be efficient antiviral compounds in clinical trials. The advent of RNA interference now seems to be refueling hopes for decisive progress in the field of therapeutic employment of antisense strategies.
DOI: 10.1007/3-540-27262-3_13
PubMed: 16594620
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002287
- to stream PubMed, to step Curation: 002287
- to stream PubMed, to step Checkpoint: 002080
- to stream Ncbi, to step Merge: 001444
- to stream Ncbi, to step Curation: 001444
- to stream Ncbi, to step Checkpoint: 001444
Links to Exploration step
pubmed:16594620Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oligonucleotide-based antiviral strategies.</title><author><name sortKey="Schubert, S" sort="Schubert, S" uniqKey="Schubert S" first="S" last="Schubert">S. Schubert</name><affiliation wicri:level="3"><nlm:affiliation>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63, 14195, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63, 14195, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Kurreck, J" sort="Kurreck, J" uniqKey="Kurreck J" first="J" last="Kurreck">J. Kurreck</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16594620</idno><idno type="pmid">16594620</idno><idno type="doi">10.1007/3-540-27262-3_13</idno><idno type="wicri:Area/PubMed/Corpus">002287</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002287</idno><idno type="wicri:Area/PubMed/Curation">002287</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002287</idno><idno type="wicri:Area/PubMed/Checkpoint">002080</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002080</idno><idno type="wicri:Area/Ncbi/Merge">001444</idno><idno type="wicri:Area/Ncbi/Curation">001444</idno><idno type="wicri:Area/Ncbi/Checkpoint">001444</idno><idno type="wicri:doubleKey">0171-2004:2006:Schubert S:oligonucleotide:based:antiviral</idno><idno type="wicri:Area/Main/Merge">003F71</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Oligonucleotide-based antiviral strategies.</title><author><name sortKey="Schubert, S" sort="Schubert, S" uniqKey="Schubert S" first="S" last="Schubert">S. Schubert</name><affiliation wicri:level="3"><nlm:affiliation>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63, 14195, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63, 14195, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Kurreck, J" sort="Kurreck, J" uniqKey="Kurreck J" first="J" last="Kurreck">J. Kurreck</name></author></analytic><series><title level="j">Handbook of experimental pharmacology</title><idno type="ISSN">0171-2004</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>Humans</term><term>Oligonucleotides (pharmacology)</term><term>Oligonucleotides (therapeutic use)</term><term>Oligonucleotides, Antisense (pharmacology)</term><term>Oligonucleotides, Antisense (therapeutic use)</term><term>RNA, Catalytic (pharmacology)</term><term>RNA, Catalytic (therapeutic use)</term><term>RNA, Small Interfering (pharmacology)</term><term>RNA, Small Interfering (therapeutic use)</term><term>Virus Diseases (drug therapy)</term><term>Virus Diseases (virology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN catalytique (pharmacologie)</term><term>ARN catalytique (usage thérapeutique)</term><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Humains</term><term>Maladies virales (traitement médicamenteux)</term><term>Maladies virales (virologie)</term><term>Oligonucléotides (pharmacologie)</term><term>Oligonucléotides (usage thérapeutique)</term><term>Oligonucléotides antisens (pharmacologie)</term><term>Oligonucléotides antisens (usage thérapeutique)</term><term>Petit ARN interférent (pharmacologie)</term><term>Petit ARN interférent (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Oligonucleotides</term><term>Oligonucleotides, Antisense</term><term>RNA, Catalytic</term><term>RNA, Small Interfering</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Oligonucleotides</term><term>Oligonucleotides, Antisense</term><term>RNA, Catalytic</term><term>RNA, Small Interfering</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>ARN catalytique</term><term>Antiviraux</term><term>Oligonucléotides</term><term>Oligonucléotides antisens</term><term>Petit ARN interférent</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies virales</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>ARN catalytique</term><term>Antiviraux</term><term>Oligonucléotides</term><term>Oligonucléotides antisens</term><term>Petit ARN interférent</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Maladies virales</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Virus Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the age of extensive global traffic systems, the close neighborhood of man and livestock in some regions of the world, as well as inadequate prevention measures and medical care in poorer countries, greatly facilitates the emergence and dissemination of new virus strains. The appearance of avian influenza viruses that can infect humans, the spread of the severe acute respiratory syndrome (SARS) virus, and the unprecedented raging of human immunodeficiency virus (HIV) illustrate the threat of a global virus pandemic. In addition, viruses like hepatitis B and C claim more than one million lives every year for want of efficient therapy. Thus, new approaches to prevent virus propagation are urgently needed. Antisense strategies are considered a very attractive means of inhibiting viral replication, as oligonucleotides can be designed to interact with any viral RNA, provided its sequence is known. The ensuing targeted destruction of viral RNA should interfere with viral replication without entailing negative effects on ongoing cellular processes. In this review, we will give some examples of the employment of antisense oligonucleotides, ribozymes, and RNA interference strategies for antiviral purposes. Currently, in spite of encouraging results in preclinical studies, only a few antisense oligonucleotides and ribozymes have turned out to be efficient antiviral compounds in clinical trials. The advent of RNA interference now seems to be refueling hopes for decisive progress in the field of therapeutic employment of antisense strategies.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F71 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003F71 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:16594620
|texte= Oligonucleotide-based antiviral strategies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:16594620" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |